Una revisión en profundidad | 01 DIC 19

Métodos no narcóticos de manejo del dolor

Actualización sobre diversas opciones de manejo del dolor sin el uso de narcóticos
Autor/a: Nanna B. Finnerup N Engl J Med 2019;380:2440-8
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

1. Merskey H, Bogduk N. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. 2nd ed. Seattle: IASP Press, 1994 (https://www.iasp-pain.org/ Publications

News/ Content.aspx?ItemNumber=1673).

2. Treede R-D, Rief W, Barke A, et al. Chronic pain as a symptom or a disease: the IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019; 160: 19-27.

3. Cordell WH, Keene KK, Giles BK, Jones JB, Jones JH, Brizendine EJ. The high prevalence of pain in emergency medical care. Am J Emerg Med 2002; 20: 165-9.

4. Sinatra R. Causes and consequences of inadequate management of acute pain. Pain Med 2010; 11: 1859-71.

5. Kent ML, Tighe PJ, Belfer I, et al. The ACTTION-APS-AAPM Pain Taxonomy (AAAPT) multidimensional approach to classifying acute pain conditions. J Pain 2017; 18: 479-89.

6. Rice AS, Smith BH, Blyth FM. Pain and the global burden of disease. Pain 2016; 157: 791-6.

7. Ballantyne JC. The brain on opioids. Pain 2018; 159: Suppl 1: S24-S30.

8. Ballantyne JC, Bhatnagar S, Blyth F, et al. IASP statement on opioids. Washington, DC: International Association for the Study of Pain, February 2018 (http://www.iasp-pain.org/Advocacy/ Content.aspx?ItemNumber=7194).

9. Ballantyne JC, Sullivan MD. Intensity of chronic pain — the wrong metric? N Engl J Med 2015; 373: 2098-9.

10. Edwards RR, Dworkin RH, Sullivan MD, Turk DC, Wasan AD. The role of psychosocial processes in the development and maintenance of chronic pain. J Pain 2016; 17: Suppl: T70-T92.

11. Jordan KP, Sim J, Croft P, Blyth F. Pain that does not interfere with daily life — a new focus for population epidemiology and public health? Pain 2019; 160: 281-5.

12. The Interagency Pain Research Coordinating Committee. National Pain Strategy: a comprehensive population health level strategy for pain. 2018 (https://iprcc.nih.gov/sites/default/ files/HHSNational_Pain_Strategy_508C.pdf).

13. Gordon DB, Dahl JL, Miaskowski C, et al. American Pain Society recommendations for improving the quality of acute and cancer pain management: American Pain Society Quality of Care Task Force. Arch Intern Med 2005; 165: 1574-80.

14. Clinical guidelines — low back pain and sciatica in over 16s: assessment and management. London: National Institute for Health and Care Excellence, 2016.

15. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2017; 166: 514-30.

16. Markozannes G, Aretouli E, Rintou E, et al. An umbrella review of the literature on the effectiveness of psychological interventions for pain reduction. BMC Psychol 2017; 5: 31.

17. Eccleston C, Crombez G. Advancing psychological therapies for chronic pain. F1000Res 2017; 6: 461.

18. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. Cochrane Database Syst Rev 2014; 9: CD000963.

19. Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology (Oxford) 2008; 47: 670-8.

20. Heiskanen T, Roine RP, Kalso E. Multidisciplinary pain treatment — which patients do benefit? Scand J Pain 2012; 3: 201-7.

21. Häuser W, Hagl M, Schmierer A, Hansen E. The efficacy, safety and applications of medical hypnosis. Dtsch Arztebl Int 2016; 113: 289-96.

22. FDA Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. Silver Spring, MD: Food and Drug Administration (https://www.fda.gov/drugs/drug -safety-and-availability/fda-drug-safety-communication-prescription-acetaminophen-products-be-limited-325-mg-dosage-unit).

23. FDA Drug Safety Communication: FDA has reviewed possible risks of pain medicine use during pregnancy. Silver Spring, MD: Food and Drug Administration (https://www.fda.gov/drugs/drug -safety-and-availability/fda-drug-safety-communication-fda-has-reviewed-possible-risks-pain-medicine-use-during-pregnancy).

24. Ho KY, Gwee KA, Cheng YK, Yoon KH, Hee HT, Omar AR. Nonsteroidal antiinflammatory drugs in chronic pain: implications of new data for clinical practice. J Pain Res 2018; 11: 1937-48.

25. American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology 2012; 116: 248-73.

26. Holbech JV, Bach FW, Finnerup NB, Brøsen K, Jensen TS, Sindrup SH. Imipramine and pregabalin combination for painful polyneuropathy: a randomized controlled trial. Pain 2015; 156: 958-66.

27. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain 2005; 116: 109-18.

28. Rintala DH, Holmes SA, Courtade D, Fiess RN, Tastard LV, Loubser PG. Comparison of the effectiveness of amitriptyline and gabapentin on chronic neuropathic pain in persons with spinal cord injury. Arch Phys Med Rehabil 2007; 88: 1547-60.

29. Kremer M, Yalcin I, Goumon Y, et al. A dual noradrenergic mechanism for the relief of neuropathic allodynia by the antidepressant drugs duloxetine and amitriptyline. J Neurosci 2018; 38: 9934-54.

30. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-48.

31. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015; 14: 162-73.

32. Becker WJ, Findlay T, Moga C, Scott NA, Harstall C, Taenzer P. Guideline for primary care management of headache in adults. Can Fam Physician 2015; 61: 670-9.

33. Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia. Cochrane Database Syst Rev 2018; 2: CD010292.

34. Chou R, Deyo R, Friedly J, et al. Systemic pharmacologic therapies for low back pain: a systematic review for an American College of Physicians clinical practice guideline. Ann Intern Med 2017; 166: 480-92.

35. Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA. Pregabalin for pain in fibromyalgia in adults. Cochrane Database Syst Rev 2016; 9: CD011790.

36. Mathieson S, Maher CG, McLachlan AJ, et al. Trial of pregabalin for acute and chronic sciatica. N Engl J Med 2017; 376: 1111-20.

37. Fabritius ML, Strøm C, Koyuncu S, et al. Benefit and harm of pregabalin in acute pain treatment: a systematic review with meta-analyses and trial sequential analyses. Br J Anaesth 2017; 119: 775-91.

38. Goodman CW, Brett AS. Gabapentin and pregabalin for pain — is increased prescribing a cause for concern? N Engl J Med 2017; 377: 411-4.

39. Di Stefano G, Truini A, Cruccu G. Current and innovative pharmacological options to treat typical and atypical trigeminal neuralgia. Drugs 2018; 78: 1433-42.

40. Cruccu G, Garcia-Larrea L, Hansson P, et al. EAN guidelines on central neurostimulation therapy in chronic pain conditions. Eur J Neurol 2016; 23: 1489-99.

41. Chen L, Michalsen A. Management of chronic pain using complementary and integrative medicine. BMJ 2017; 357: j1284.

42. Taylor SL, Herman PM, Marshall NJ, et al. Use of complementary and integrated health: a retrospective analysis of U.S. veterans with chronic musculoskeletal pain nationally. J Altern Complement Med 2019; 25: 32-9.

43. Berman BM, Langevin HM, Witt CM, Dubner R. Acupuncture for chronic low back pain. N Engl J Med 2010; 363: 454-61.

44. Martel MO, Finan PH, Dolman AJ, et al. Self-reports of medication side effects and pain-related activity interference in patients with chronic pain: a longitudinal cohort study. Pain 2015; 156: 1092-100.

45. Chang DS, Raghavan R, Christiansen S, Cohen SP. Emerging targets in treating pain. Curr Opin Anaesthesiol 2015; 28: 379-97.

46. Bouhassira D, Attal N. Emerging therapies for neuropathic pain: new molecules or new indications for old treatments? Pain 2018; 159: 576-82.

47. Todd KH. A review of current and emerging approaches to pain management in the emergency department. Pain Ther 2017; 6: 193-202.

48. Pitchon DN, Dayan AC, Schwenk ES, Baratta JL, Viscusi ER. Updates on multimodal analgesia for orthopedic surgery. Anesthesiol Clin 2018; 36: 361-73.

49. Themistocleous AC, Crombez G, Baskozos G, Bennett DL. Using stratified medicine to understand, diagnose, and treat neuropathic pain. Pain 2018; 159: Suppl 1: S31-S42.

50. Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo controlled phenotype-stratified study. Pain 2014; 155: 2263-73.



Usted debe ingresar al sitio con su cuenta de usuario IntraMed para ver los comentarios de sus colegas o para expresar su opinión. Si ya tiene una cuenta IntraMed o desea registrase, ingrese aquí